G1 Therapeutics Company Overview
About G1 Therapeutics
G1 Therapeutics (NASDAQ:GTHX) is a biopharmaceutical company dedicated to discovering, developing, and delivering innovative treatments for patients battling cancer. With a robust pipeline that focuses on lung cancer and other solid tumors, G1 Therapeutics is committed to advancing its lead product candidates through clinical trials, aiming to improve outcomes for patients with these challenging diseases. The company's research primarily targets novel mechanisms of action, with a particular emphasis on cell cycle science, to disrupt cancer cell growth and proliferation. The ultimate objective of G1 Therapeutics is to provide new, more effective therapies that can significantly improve the quality of life for patients impacted by cancer, while also striving for advancements that can transform cancer treatment paradigms.
Snapshot
Operations
Products and/or services of G1 Therapeutics
- COSELA (trilaciclib), a therapy designed to help protect bone marrow from damage due to chemotherapy, aimed at improving patient outcomes in cancer treatments.
- Clinical development of rintodestrant, an oral SERD for estrogen receptor-positive (ER+) breast cancer, focusing on offering a novel treatment option for patients.
- Lerociclib, under investigation for its potential in treating various types of cancers, including breast and lung cancers, with a focus on creating effective combination therapies.
- Ongoing research into novel therapies for myelopreservation, aiming at reducing the need for blood transfusions and growth factor support in cancer patients.
- Collaborations with pharmaceutical and biotechnology companies to accelerate the development and commercialization of their oncology portfolio, leveraging strategic partnerships.
- Commitment to advancing a pipeline of targeted therapies that address unmet needs in the treatment of cancer, emphasizing patient-centric solutions.
G1 Therapeutics executive team
- Mr. John E. Bailey Jr.CEO, President & Director
- Dr. Rajesh K. Malik Ch.B., M.B., M.D.Chief Medical Officer
- Mr. Mark AvaglianoChief Business Officer
- Mr. John W. Umstead VChief Financial Officer
- Mr. Terry L. Murdock MScChief Operating Officer
- Mr. William C. RobertsVice President of Investor Relations & Corporate Communications
- Ms. Monica Roberts ThomasChief Legal & People Officer
- Mr. Evan Hicks M.B.A.Vice President of Marketing
- Mr. Andrew PerryChief Commercial Officer
- Mr. Jeff MacdonaldSenior Director of Investor Relations & Corporate Communications